Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Kratom Regulation topic
No spam. Unsubscribe anytime.
Committee hears concerns about kratom, carries S.221 over for further review
Summary
Committee members discussed health and addiction concerns tied to kratom products, considered two regulatory approaches used by other states and voted to carry S.221 over to a later Medical Affairs Committee meeting for additional research.
Senators in the Medical Affairs Committee discussed S.221, a bill seeking to regulate kratom products, and voted to carry the measure over for further study.
Committee staff summarized two common state approaches: outright bans, which several states have adopted (some by regulation), and consumer-protection frameworks that regulate product composition, restrict sales by age and set civil penalties. The draft before the committee would regulate kratom as a consumer product with an age restriction (the bill text referenced an over-21 requirement) and monetary penalties for violations (first offense: $500; subsequent offense: $1,000).
Senators said they had differing levels of familiarity with kratom. One senator described cases of kratom use among people trying to quit opioids and said two of her clients developed kratom dependence; one required emergency-room treatment for psychiatric symptoms. Senators asked whether federal policy addresses kratom and staff said no federal policy is in place and that states have taken differing approaches. Several senators asked for more time to research the substance, its prevalence, clinical harms and regulatory models; the committee voted to carry S.221 over to the committee's next meeting so members can review additional information.
The committee will reconvene in full committee on the first Thursday in March; the chair set the next full committee date as March 6. The motion to carry over S.221 passed by voice vote.
